Dihydrexidine  (Synonyms: DAR-0100)

Dihydrexidine (DAR-0100) is a high potent, selective and full efficacy D1-like dopamine receptor (D1/D5) agonist with an IC₅₀ of 10 nM for D1 receptor. Dihydrexidine exhibits potent antiparkinsonian activity^[1][2][3][4]. Dihydrexidine can stimulate YAP phosphorylation^[5].

IC50: 10 nM (D1 dopamine receptor), D5 dopamine receptor, 660 nM (D1 dopamine receptor)^[1]

Dihydrexidine (DAR-0100) strongly increased YAP phosphorylation in U2OS cells^[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Dihydrexidine has poor oral bioavailability and a relatively short half-life of 1 to 2 h^[3].
Dihydrexidine (3 mg/kg; i.p.) produces prominent dopamine D1 receptor agonist effects in vivo^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

267.32

C₁₇H₁₇NO₂

123039-93-0

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Lovenberg TW, et al. Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist. Eur J Pharmacol. 1989 Jul 4;166(1):111-3.  [Content Brief]

  [2]. Mottola DM, et al. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. J Pharmacol Exp Ther. 1992 Jul;262(1):383-93.  [Content Brief]

  [3]. Salmi P,et al. Dihydrexidine--the first full dopamine D1 receptor agonist. CNS Drug Rev. 2004 Fall;10(3):230-42.  [Content Brief]

  [4]. Gleason, S. D., et al. Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine. Psychopharmacology, 2006;186(1), 25–31.  [Content Brief]

  [5]. Yu FX, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012;150(4):780-791.  [Content Brief]